The bulls here are wondering "how can the share price action be so terrible if PGEN is making so much progress?"
Hasn't the company made so much progress in the past year to warrant a share price higher than a year ago ?
The wise poster "cptspr" told me to take a look at AUPH when it was $12 this spring. It had been over $20 a few months earlier in January. He was convinced it would be a big winner. The stock fell to $10 and I wrote some $10 puts which made me a few bucks but I questioned cptspr's judgement as a $2 drop from $12 to $10 wasn't the price action I expected from a winning stock.
He stayed with the stock and in the past five months it has rallied from $10 in May to $28 with some thinking BMY may buy it out at much higher prices.
1-25-21 . . . $20.50. . . . FDA Approves Aurina Lupkynis
5-6-21 . . . $12.34. . . . Q-1 results reported after the close
5-7-21 . . . .$10.00 . . . investors sell the stock - don't like Q-1 results
5-11-21 . . $11.23 . .. Phase 3 meets primary endpoint . . . investors like the news
7-26-21 . . .$10.93 . . . investors bored
8-9-21 . . . .$15.70 . . investors getting warmed up to the story
8-19-21. . . $13.00 . . .. investors getting bored and impatient
10-22-21 . .. $28 . . .. . News services reporting potential buyout by BMY for $60
The moral : the market doesn't always get it "right" in the short term.
I agree with the 809trader that the "smart money" the past few years was those short XON/PGEN. But they have been buying the stock this past year even as Merck sold 6+ million shares. Only eight more trading sessions until we get to know "if" Helen really has good reason to be so very "excited".